Ultrasound sales turn up for Acuson
Acuson last week downplayedan improvement in its ultrasound sales and net income for thefirst quarter of 1994 (end April 2). However, the results weregood news for the vendor and an ultrasound industry battered bydeclining U.S. purchasing. Net sales
Acuson last week downplayedan improvement in its ultrasound sales and net income for thefirst quarter of 1994 (end April 2). However, the results weregood news for the vendor and an ultrasound industry battered bydeclining U.S. purchasing.
Net sales for the first quarter rose 12% from $82.3 millionin 1993 to $92.8 million this year. Net income shot up a strong31% from $5 million in the first quarter of last year to $6.6million in the same period this year.
"Our first quarter financial results may not be indicativeof the results for the entire year," said Samuel H. Maslak,president and CEO. "Market uncertainties regarding the purchaseof hospital medical equipment will persist for an indeterminateperiod, due to ongoing worldwide medical cost containment pressuresand concern about the potential impacts of U.S. health-care reform."
Acuson may be right in downplaying a possible market upturn.Ultrasound competitor ATL saw revenue drop 6% for the same three-monthperiod, from $81.4 million in 1993 to $75.9 million this year.
"We expect the difficult market conditions in the U.S.to continue for the near term," said Dennis C. Fill, chairmanand CEO.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
